Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Southampton Eye Unit Offers Uk's Most Advanced Corneal Surgery
Two of the UK"s top ophthalmologists based at Southampton General Hospital"s Eye Unit are offering the most advanced treatment for corneal disease in the country.
generic viagra online
Is There Any Association Between COX2 And Colon Cancer?
Non-steroidal anti-inflammatory drugs (NSAIDs), which are known to reduce the risk of colon cancer, act directly on cyclooxygenase-2 (COX2) and reduce its activity. Population studies have found an association of inherited variations in the COX2 gene with colon cancer risk, but others were unable to replicate this finding. Similarly, variations in the uridine diphosphate glucuronosyltransferase 1A6 (UGT1A6) gene, which is also known to be key in the metabolism of NSAIDs, have been shown to modify the effect of NSAIDs on developing colon polyps, a precursor of colon cancer, but these modifications of NSAID effects have not been observed in risk of colon cancer.
News of the day
Better Classification And Treatment Of Juvenile Arthritis Via Gene Expression
Scientists have discovered gene expression differences that could lead to better ways to classify, predict outcome, and treat juvenile idiopathic arthritis (JIA). Eventually such findings could enable doctors to target more aggressive treatment to children at risk of more severe arthritis, while those likely to have milder disease could be spared the stronger treatments that carry a greater risk of side effects. The researchers were supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health.
Public Health

AIMSPRO Is Awarded TGA Orphan Status For The Treatment Of Amyotrophic Lateral Sclerosis

Privately owned UK biotech company Daval International Limited has been informed by Australia"s Therapeutic Goods Administration (TGA) that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded Orphan Status for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS is the most common form of Motor Neuron Disease (MND), also known as Lou Gehrig"s disease. AIMSPRO has already achieved TGA Orphan Status for the treatment of Krabbe Leukodystrophy (Krabbe"s disease). Daval is now evaluating an international, multi-centre, placebo controlled, Randomised Clinical Trial to determine whether later stage ALS patients with poor respiratory function can be seen to benefit from the medication under double-blind conditions. AIMSPRO is a new generation biological medicine which is d and manufactured in Australia. It is derived from hyperimmune caprine serum and is currently under Phase II trialling in Europe for advanced Scleroderma and for bladder dysfunction in Secondary Progressive Multiple Sclerosis. Both trials are expected to report in the first quarter of 2010. Additional open label experience with AIMSPRO, over an extended period, has led Daval to consider Proof of Concept studies in Adhesive Arachnoiditis, treatment resistant Myasthenia Gravis and Psoriatic arthritis. AIMSPRO is listed on the Export Only section of the Australian Therapeutic Goods Registry and is imported into Europe by Biotec Distribution (Wales) Limited for clinical trial and "named patient use" purposes. The veterinary form of the product, Ceremben(R) has shown efficacy, safety and tolerability in studies addressing critically important indications in standardbred and thoroughbred horses. The Australian regulator, the APVMA, has recently awarded Ceremben a Research Permit, which will enable confirmatory equine field trials to be rapidly completed. Ceremben is also being developed as a potential canine and feline anti-inflammatory agent. Daval International Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009